Cargando…

Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer

OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Liu, Yanxia, Zhang, Lina, Tong, Li, Gao, Yuan, Hu, Fanbin, Lin, Peter Ping, Li, Baolan, Zhang, Tongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861204/
https://www.ncbi.nlm.nih.gov/pubmed/31646374
http://dx.doi.org/10.1007/s00432-019-03040-9
_version_ 1783471301641371648
author Wang, Ying
Liu, Yanxia
Zhang, Lina
Tong, Li
Gao, Yuan
Hu, Fanbin
Lin, Peter Ping
Li, Baolan
Zhang, Tongmei
author_facet Wang, Ying
Liu, Yanxia
Zhang, Lina
Tong, Li
Gao, Yuan
Hu, Fanbin
Lin, Peter Ping
Li, Baolan
Zhang, Tongmei
author_sort Wang, Ying
collection PubMed
description OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy. RESULTS: Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim(+) CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim(+) CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim(+) CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim(+) CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim(+) CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239–6.131; p = 0.013]. CONCLUSIONS: This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim(+) CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim(+) CTCs is correlated with liver metastases and may help predict poor PFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03040-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6861204
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-68612042019-12-03 Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer Wang, Ying Liu, Yanxia Zhang, Lina Tong, Li Gao, Yuan Hu, Fanbin Lin, Peter Ping Li, Baolan Zhang, Tongmei J Cancer Res Clin Oncol Original Article – Cancer Research OBJECTIVE: To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer. METHODS: Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy. RESULTS: Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim(+) CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim(+) CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim(+) CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim(+) CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim(+) CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239–6.131; p = 0.013]. CONCLUSIONS: This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim(+) CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim(+) CTCs is correlated with liver metastases and may help predict poor PFS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03040-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-10-23 2019 /pmc/articles/PMC6861204/ /pubmed/31646374 http://dx.doi.org/10.1007/s00432-019-03040-9 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article – Cancer Research
Wang, Ying
Liu, Yanxia
Zhang, Lina
Tong, Li
Gao, Yuan
Hu, Fanbin
Lin, Peter Ping
Li, Baolan
Zhang, Tongmei
Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title_full Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title_fullStr Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title_full_unstemmed Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title_short Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
title_sort vimentin expression in circulating tumor cells (ctcs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
topic Original Article – Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861204/
https://www.ncbi.nlm.nih.gov/pubmed/31646374
http://dx.doi.org/10.1007/s00432-019-03040-9
work_keys_str_mv AT wangying vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT liuyanxia vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT zhanglina vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT tongli vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT gaoyuan vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT hufanbin vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT linpeterping vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT libaolan vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer
AT zhangtongmei vimentinexpressionincirculatingtumorcellsctcsassociatedwithlivermetastasespredictspoorprogressionfreesurvivalinpatientswithadvancedlungcancer